1. From Good to Better: New Dutch Guidelines for Economic Evaluations in Healthcare

   • Matthijs Versteegh
   • Saskia Knies
   • Werner Brouwer

   Editorial 09 September 2016 Pages: 1071 - 1074

2. Estimating Marginal Healthcare Costs Using Genetic Variants as Instrumental Variables: Mendelian Randomization in Economic Evaluation

   • Padraig Dixon
   • George Davey Smith
   • William Hollingworth

   Practical Application Open access 02 August 2016 Pages: 1075 - 1086

   

3. Economic and Humanistic Burden of Osteoarthritis: A Systematic Review of Large Sample Studies

   • Feng Xie
   • Bruno Kovic
   • Camila Silvestre

   Systematic Review 23 June 2016 Pages: 1087 - 1100

   

4. The Clinical and Cost Effectiveness of Apremilast for Treating Active Psoriatic Arthritis: A Critique of the Evidence

   • Eleftherios Sideris
   • Mark Corbett
   • Laura Bojke

   Review Article 08 June 2016 Pages: 1101 - 1110

   

5. A Methodological Review of US Budget-Impact Models for New Drugs

   • Josephine Mauskopf
   • Stephanie Earnshaw

   Review Article 22 June 2016 Pages: 1111 - 1131

6. Impact on the Incremental Cost-Effectiveness Ratio of Using Alternatives to EQ-5D in a Markov Model for Multiple Sclerosis

   • Matthijs Versteegh

   Original Research Article Open access 09 June 2016 Pages: 1133 - 1144

   

7. Cost Effectiveness of Characterised Chondrocyte Implantation for Treatment of Cartilage Defects of the Knee in the UK

   • Jamie Elvidge
   • Ash Bullement
   • Anthony J. Hatswell

   Original Research Article 18 June 2016 Pages: 1145 - 1159

   

8. Reporting Guidelines for the Use of Expert Judgement in Model-Based Economic Evaluations

   • Cynthia P. Iglesias
   • Alexander Thompson
   • Katherine Payne

   Original Research Article 30 June 2016 Pages: 1161 - 1172

   

9. Competition Between Biosimilars and Patented Biologics: Learning from European and Japanese Experience

   • François Bocquet
   • Anaïs Loubière
   • Pascal Paubel

   Original Research Article 13 July 2016 Pages: 1173 - 1186

   

10. Discretely Integrated Condition Event Simulation for Pharmacoeconomics

    • Mondher Toumi
    • Ekkehard Beck
    • Samuel Aballéa

    Letter to the Editor 14 September 2016 Pages: 1187 - 1188

11. Response to Letter to the Editor Regarding Discretely Integrated Condition Event Simulation for Pharmacoeconomics

    • J. Jaime Caro

    Letter to the Editor 12 September 2016 Pages: 1189 - 1190